The Relations between Serum Leptin Level with Disease Activity and Inflammatory Markers in Fibromyalgia Patients

Ataoğlu, Safinaz; Ankaralı, Handan; Samanci, Rümeysa; Özşahin, Mustafa; Admis, Ozlem

doi:10.14744/nci.2017.31644

Cited by 10 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Meta-analysis was performed using RevMan analysis software (RevMan 5.4) of the Cochrane Collaboration. 4 Meta-analysis was executed for individual blood biomarkers whenever values of the levels of these biomarkers were available in 3 or more studies. All values were reported in picogram per milliliter (pg/mL); BDNF, GH, and IGH values were reported in nanogram (ng) per ml, whereas CRP values were reported in mg per dL.…”

Section: Stage 4: Meta-analysis and Meta-regressionmentioning

confidence: 99%

Potential role of blood biomarkers in patients with fibromyalgia: a systematic review with meta-analysis

Kumbhare

Hassan

Diep

et al. 2021

PAIN

View full text Add to dashboard Cite

show abstract

Section: Stage 4: Meta-analysis and Meta-regressionmentioning

confidence: 99%

Potential role of blood biomarkers in patients with fibromyalgia: a systematic review with meta-analysis

Kumbhare

Hassan

Diep

et al. 2021

PAIN

View full text Add to dashboard Cite

show abstract

“…One study reported simultaneous elevation of ESR and leptin and CRP levels in some hemodialysis patients, but the authors suggested that it was BMI, but not the two inflammatory markers that had a significant correlation with leptin . High leptin level was also found in fibromyalgia patients without a firm relationship with ESR and CRP levels, implying its poor capacity to indicate disease activity . However, the involvement of leptin in systemic inflammation was still confirmed in the two studies above, as well as many other studies focused on rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), immunoglobulin A (IgA) vasculitis and Behçet's disease .…”

Section: Discussionmentioning

confidence: 53%

Serum leptin, a potential predictor of long‐term angiographic progression in Takayasu’s arteritis

Dai

et al. 2019

Int J of Rheum Dis

View full text Add to dashboard Cite

Aim:In patients with Takayasu's arteritis (TA), current biomarkers that properly reflect the progression of the vascular structure remain absent. We aimed to determine the serum leptin level to investigate its relationship with imaging changes and assess its value as a predictor for long-term radiological progression. Method:This study included 34 untreated TA patients and 40 age-matched healthy controls. At baseline and during the 5-year follow-up, we assessed disease activity using Kerr's criteria and Indian Takayasu Clinical Activity Score (ITAS2010) and monitored laboratory biomarkers as well as imaging findings. Serum leptin levels were measured by enzyme-linked immunosorbent assay. Results:The baseline serum leptin levels were significantly higher in TA patients than in healthy controls. Leptin was significantly positively correlated with triglyceride and high-density lipoprotein cholesterol levels and negatively correlated with fibrinogen and C-reactive protein levels. Patients were subdivided into three groups based on their baseline leptin level. During a 5-year follow-up, patients in the high and medium leptin groups showed more radiological progression compared to those in the low leptin group. Cox proportional hazard regression analysis showed that a high serum leptin level was a positive predictor of radiological progression. Conclusion:Leptin is a potential biomarker for assessing TA structural progression.Untreated patients with elevated serum leptin levels are at a higher risk of progression in the aorta. Thus, the leptin level can be a predictor of long-term radiological progression. K E Y W O R D S disease progression, leptin, radiography, Takayasu's arteritis | 2135 MA et Al.

show abstract

“…2 ). TGs also correlated with hsCRP ln (ρ[ 36 ] = 0.370, P = 0.024). No other measures correlated significantly with hsCRP ln (STAI-B ρ[ 32 ] = 0.162, P = 0.359; PCS ρ[ 34 ] = 0.194, P = 0.256; glucose ρ[ 35 ] = 0.167, P = 0.322; glucose AUC ρ[ 33 ] = 0.107, P = 0.542; HDL ρ[ 35 ] = −0.0047, P = 0.978; LDL ρ[ 35 ] = 0.201, P = 0.233).…”

Section: Resultsmentioning

confidence: 97%

Elevated highly sensitive C-reactive protein in fibromyalgia associates with symptom severity

Zetterman

Markkula

Kalso

2022

Rheumatology Advances in Practice

View full text Add to dashboard Cite

OBJECTIVES Fibromyalgia, a common pain syndrome, is thought to be a non-inflammatory, nociplastic condition but evidence implicating neuroinflammation has been increasing. Systemic inflammation may be associated with more severe symptoms in some fibromyalgia patients. We studied healthy controls and fibromyalgia patients with and without systemic inflammation detectable using high-sensitivity C-reactive protein (hsCRP) measurement. METHODS We measured hsCRP levels, and gathered clinical and questionnaire data (including Fibromyalgia Impact Questionnaire (FIQ)), from 40 female fibromyalgia patients and 30 age-matched healthy women: hsCRP > 3 mg/l was considered elevated. RESULTS Fibromyalgia patients had significantly higher mean hsCRP levels than controls, explained by overweight and lower leisure-time physical activity. Eight fibromyalgia patients had elevated, and 29 normal, hsCRP. Levels of hsCRP were significantly correlated with FIQ scores. Patients with elevated hsCRP had higher FIQ scores, with worse physical functioning and greater pain, and were less likely to be in work, than patients with normal hsCRP. These patient groups did not differ by blood count, liver function, or lipid profiles, nor by education, psychological measures, sleep disturbance, smoking, or comorbidities. CONCLUSION Some fibromyalgia patients have elevated hsCRP, mostly due to overweight and physical inactivity. They have worse symptoms and their ability to work is impaired. Measurement of hsCRP may help to identify fibromyalgia patients in greatest need of interventions supporting working ability. TRIAL REGISTRATION ClinicalTrials.gov, https://clinicaltrials.gov, NCT03300635 Lay summary What does this mean for patients? People with fibromyalgia suffer from persistent pain and reduced physical functioning. Severity of fibromyalgia symptoms varies greatly between patients. Laboratory tests have not been able to confirm fibromyalgia or gauge its severity. C-reactive protein (CRP) is a commonly used indicator of inflammation; even low levels of inflammation are known to predict worse health outcomes. In our study, we measured the CRP levels of 40 female patients with fibromyalgia and collected data on their medical history and lifestyle factors. We found that patients with above normal levels of CRP had worse symptoms, lower physical functioning and were less likely to be able to work. This increased inflammation was mostly explained by being overweight and having reduced physical activity, and not by, for example, other medical conditions. Although some patients had severe symptoms without inflammation, our results suggest that a simple and widely available blood test could be useful for identifying patients with severe fibromyalgia. CRP measurements could also be used to monitor the effectiveness of lifestyle changes such as exercise and weight-loss in these individuals. Using medication to alleviate fibromyalgia symptoms through reduction of inflammation should also be studied in the future.

show abstract

The Relations between Serum Leptin Level with Disease Activity and Inflammatory Markers in Fibromyalgia Patients

Cited by 10 publications

References 34 publications

Potential role of blood biomarkers in patients with fibromyalgia: a systematic review with meta-analysis

Potential role of blood biomarkers in patients with fibromyalgia: a systematic review with meta-analysis

Serum leptin, a potential predictor of long‐term angiographic progression in Takayasu’s arteritis

Elevated highly sensitive C-reactive protein in fibromyalgia associates with symptom severity

Contact Info

Product

Resources

About